See more : Auriant Mining AB (publ) (AUR.ST) Income Statement Analysis – Financial Results
Complete financial analysis of UroGen Pharma Ltd. (URGN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of UroGen Pharma Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Pure H20 Bio-Technologies, Inc. (PRHB) Income Statement Analysis – Financial Results
- IRM Energy Limited (IRMENERGY.NS) Income Statement Analysis – Financial Results
- Chinese Gamer International Corporation (3083.TWO) Income Statement Analysis – Financial Results
- Enlighta Inc. (NLTA.V) Income Statement Analysis – Financial Results
- Federal National Mortgage Association (FNMAJ) Income Statement Analysis – Financial Results
UroGen Pharma Ltd. (URGN)
About UroGen Pharma Ltd.
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 82.71M | 64.36M | 48.04M | 11.80M | 18.00K | 1.13M | 8.16M | 17.53M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 9.36M | 7.65M | 5.16M | 1.01M | 0.00 | 1.80M | 600.00K | 28.00K | 113.00K | 0.00 | 0.00 |
| Gross Profit | 73.35M | 56.70M | 42.89M | 10.79M | 18.00K | -675.00K | 7.56M | 17.50M | -113.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 88.68% | 88.11% | 89.27% | 91.45% | 100.00% | -59.84% | 92.65% | 99.84% | 0.00% | 0.00% | 0.00% |
| Research & Development | 45.61M | 52.91M | 47.64M | 47.31M | 49.30M | 36.93M | 18.70M | 10.29M | 10.52M | 4.01M | 2.33M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 60.20M | 39.57M | 8.81M | 6.42M | 1.90M | 890.00K | 1.06M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 93.27M | 82.84M | 87.54M | 90.22M | 60.20M | 39.57M | 8.81M | 6.42M | 1.90M | 890.00K | 1.06M |
| Other Expenses | 0.00 | 72.00K | 0.00 | 0.00 | -284.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 138.89M | 135.74M | 135.18M | 137.53M | 109.50M | 76.51M | 27.51M | 16.70M | 12.41M | 4.36M | 3.39M |
| Cost & Expenses | 148.25M | 143.40M | 140.33M | 138.54M | 109.50M | 78.31M | 28.11M | 16.73M | 12.41M | 4.36M | 3.39M |
| Interest Income | 2.64M | 1.01M | 212.00K | 1.63M | 4.62M | 1.87M | 0.00 | 1.00K | 0.00 | 120.00K | 83.00K |
| Interest Expense | 14.72M | 8.44M | 17.44M | 357.00K | 284.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.71M | 1.82M | 1.77M | 2.04M | 1.32M | 417.00K | 207.00K | 213.00K | 113.00K | 30.00K | 18.00K |
| EBITDA | -63.83M | -78.03M | -90.15M | -122.71M | -108.15M | -77.18M | -19.74M | 1.01M | -12.30M | -4.34M | -3.37M |
| EBITDA Ratio | -77.17% | -121.25% | -156.12% | -1,074.15% | -600,855.56% | -6,842.20% | -244.55% | 5.77% | 0.00% | 0.00% | 0.00% |
| Operating Income | -65.54M | -79.04M | -92.29M | -126.74M | -109.48M | -77.18M | -19.95M | 798.00K | -12.41M | -4.37M | -3.39M |
| Operating Income Ratio | -79.23% | -122.82% | -192.11% | -1,074.15% | -608,211.11% | -6,842.20% | -244.55% | 4.55% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -32.79M | -28.99M | -17.08M | 1.63M | 4.33M | 1.65M | -31.00K | -2.74M | -279.00K | -107.00K | 83.00K |
| Income Before Tax | -98.32M | -108.03M | -109.37M | -125.11M | -105.15M | -75.53M | -19.98M | -1.94M | -12.69M | -4.48M | -3.31M |
| Income Before Tax Ratio | -118.87% | -167.86% | -227.66% | -1,060.34% | -584,144.44% | -6,696.10% | -244.93% | -11.07% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 3.92M | 1.14M | 1.45M | 3.37M | -4.62M | 125.00K | 19.00K | 0.00 | 0.00 | 81.00K | 0.00 |
| Net Income | -102.24M | -109.16M | -110.82M | -128.48M | -100.53M | -75.66M | -20.00M | -1.94M | -12.69M | -4.56M | -3.31M |
| Net Income Ratio | -123.61% | -169.62% | -230.67% | -1,088.94% | -558,500.00% | -6,707.18% | -245.16% | -11.07% | 0.00% | 0.00% | 0.00% |
| EPS | -3.55 | -4.79 | -4.96 | -5.90 | -4.90 | -4.80 | -2.06 | -0.16 | -5.51 | -1.98 | -1.56 |
| EPS Diluted | -3.55 | -4.79 | -4.96 | -5.90 | -4.90 | -4.80 | -2.06 | -0.16 | -5.51 | -1.98 | -1.56 |
| Weighted Avg Shares Out | 28.83M | 22.81M | 22.35M | 21.78M | 20.53M | 15.75M | 9.72M | 11.97M | 2.30M | 2.30M | 2.12M |
| Weighted Avg Shares Out (Dil) | 28.83M | 22.81M | 22.35M | 21.78M | 20.53M | 15.75M | 9.72M | 11.97M | 2.30M | 2.30M | 2.12M |
UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference
UroGen Announces FDA Acceptance of its New Drug Application for UGN-102
UroGen Pharma to Present at Upcoming Investor Conferences
UroGen Pharma Ltd. (URGN) Q2 2024 Earnings Call Transcript
Urogen Pharma (URGN) Reports Q2 Loss, Misses Revenue Estimates
Does Urogen Pharma (URGN) Have the Potential to Rally 171.05% as Wall Street Analysts Expect?
Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy?
Wall Street Analysts See a 149.01% Upside in Urogen Pharma (URGN): Can the Stock Really Move This High?
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
Source: https://incomestatements.info
Category: Stock Reports